
    
      Patients with metastatic gastric cancer failed to first-line therapy will be radomized to arm
      A with PLD and 5-Fu and arm B with irinotecan single agent therapy. Both regimens will be
      treated every 2 weeks until disease progression or untolerable toxicity. Efficacy will be
      assessed every 3 cycles and safety will be evaluated every cycle.
    
  